Form 8-K - Current report:
SEC Accession No. 0001493152-25-025177
Filing Date
2025-11-26
Accepted
2025-11-26 17:00:46
Documents
13
Period of Report
2025-11-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 44121
  Complete submission text file 0001493152-25-025177.txt   254228

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE aktx-20251124.xsd EX-101.SCH 3810
3 XBRL DEFINITION FILE aktx-20251124_def.xml EX-101.DEF 26684
4 XBRL LABEL FILE aktx-20251124_lab.xml EX-101.LAB 36826
5 XBRL PRESENTATION FILE aktx-20251124_pre.xml EX-101.PRE 25308
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5782
Mailing Address 401 EAST JACKSON STREET SUITE 3300 TAMPA FL 33602
Business Address 401 EAST JACKSON STREET SUITE 3300 TAMPA FL 33602 (929) 274-7510
Akari Therapeutics Plc (Filer) CIK: 0001541157 (see all company filings)

EIN.: 981034922 | State of Incorp.: X0
Type: 8-K | Act: 34 | File No.: 001-36288 | Film No.: 251531221
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)